Sales of 5,216 million yen (YoY +11.2%), operating income turned positive at 201 million yen, net income attributable to owners of the parent improved to 394 million yen. For the year ending June 2027, sales are expected to be 5,650 million yen and operating income 350 million yen. Driving sales expansion of devices and reagents for genetic testing centered on the PSS platform, while cost containment is pursued. Net income significantly improves due to liquidation gains of the U.S. subsidiary and deferred tax assets recognized, among other factors.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7707","jir_company_name":"Precision System Science Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/7707-20260814-01.pdf","jir_short_summary":"Sales of 5,216 million yen (YoY +11.2%), operating income turned positive at 201 million yen, net income attributable to owners of the parent improved to 394 million yen. For the year ending June 2027, sales are expected to be 5,650 million yen and operating income 350 million yen. Driving sales expansion of devices and reagents for genetic testing centered on the PSS platform, while cost containment is pursued. Net income significantly improves due to liquidation gains of the U.S. subsidiary and deferred tax assets recognized, among other factors.","jir_summary":"### Overview of Results\nThis fiscal term's results show sales of 5,216 million yen, up 11.2% YoY. The effects of reduced selling, general and administrative expenses and restructuring contributed to turning operating income positive at 201 million yen, with ordinary income of 155 million yen. Net income attributable to owners of the parent improved to 394 million yen. By component, sales were 2,231 million yen for devices, 2,037 million yen for reagents and consumables, and 948 million yen for services and others. Sales growth from devices and nucleic acid extraction reagents using the PSS platform contributed to the improvement.\n\n### Outlook and Capital Measures\nFor the consolidated results of the year ending June 2027, sales are expected to be 5,650 million yen, operating income 350 million yen, ordinary income 298 million yen, and net income attributable to owners of the parent 292 million yen. The company plans to secure a foundation of long-term stable orders through an OEM agreement with ELITechGroup. Financially, cash flow is stable, and the company will continue expanding the PSS platform while advancing business restructuring and cost reduction to improve profitability.","jir_financial_highlights":"Sales: 5,216 (YoY 11.2% increase)\nOperating income: 201 (from previous term: negative 121 \u2192 positive)\nNet income attributable to owners of the parent: 394 (from previous term: negative 253 \u2192 positive (improvement))\nNext period outlook Sales: 5,650 (vs previous period +8.3%)\nNext period outlook Operating income: 350 (vs previous period +73.9%)","jir_category":"","jir_hashtags":"#Precision System Science, #FinancialSummary, #LifeScience, #PSSPlatform","jir_key_figures":"Sales: 5,216 million yen\nOperating income: 201 million yen\nNet income attributable to owners of the parent: 394 million yen\nNext period outlook: Sales 5,650 million yen, Operating income 350 million yen\nNumber of treasury shares: 53,603 thousand yen (end-of-term treasury share amount)","jir_meta_title":"Precision System Science: 2026 June Term Financial Summary | Sales 5,216 million yen, Turned Positive","jir_meta_description":"Summary of Precision System Science's 2026 June term financial results. Sales 5,216 million yen, operating income turned positive, net income 394 million yen. For 2027 June term, sales 5,650 million yen, operating income 350 million yen expected. PSS platform expansion and cost control pursued.","jir_og_title":"Precision System Science: 2026 June Term Financial Summary Overview","jir_og_description":"Sales of 5,216 million yen, operating income of 201 million yen turned positive, net income 394 million yen. Next period expects sales 5,650 million yen and operating income 350 million yen. Focus on expanding the PSS platform.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59741,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-104433","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n